WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010023855) C12ORF48 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/023855    International Application No.:    PCT/JP2009/004020
Publication Date: 04.03.2010 International Filing Date: 21.08.2009
IPC:
C12N 15/09 (2006.01)
Applicants: ONCOTHERAPY SCIENCE, INC. [JP/JP]; 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa 2130012 (JP) (For All Designated States Except US).
NAKAMURA, Yusuke [JP/JP]; (JP) (For US Only).
NAKAGAWA, Hidewaki [JP/JP]; (JP) (For US Only).
TOGASHI, Akira [JP/JP]; (JP) (For US Only)
Inventors: NAKAMURA, Yusuke; (JP).
NAKAGAWA, Hidewaki; (JP).
TOGASHI, Akira; (JP)
Agent: SHIMIZU, Hatsushi; (JP)
Priority Data:
61/190,529 28.08.2008 US
Title (EN) C12ORF48 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
(FR) GÈNE C12ORF48 SERVANT DE GÈNE CIBLE DANS LE TRAITEMENT ET LE DIAGNOSTIC DU CANCER
Abstract: front page image
(EN)Objective methods for diagnosing a predisposition to developing pancreatic cancer and prostate cancer, particularly pancreatic ductal adenocarcinoma (PDAC) and castration-resistant prostate cancer, are described herein. In one embodiment, the diagnostic method involves the step of determining an expression level of C12ORF48 using siRNAs targeting the C12ORF48 gene. The invention also features products such as siRNAs as well as to compositions containing them. The present invention further provides methods of screening for therapeutic agents useful in the treatment of C12ORF48 associated disease, such as a cancer, e.g. pancreatic cancer and prostate cancer, as well as methods of inhibiting the cell growth and treating or alleviating one or more disease symptoms. The invention also features products such as double stranded molecules, as well as vectors and compositions containing them.
(FR)L’invention concerne des méthodes permettant de diagnostiquer une prédisposition au développement du cancer du pancréas et du cancer de la prostate, en particulier de l’adénocarcinome canalaire pancréatique (ACP) et du cancer de la prostate résistant à castration. Dans un mode de réalisation, la méthode de diagnostic implique l’étape de détermination d’un taux d’expression du gène C12ORF48 à l’aide d’ARNsi ciblant C12ORF48. L’invention concerne aussi des produits tels que les ARNsi ainsi que des compositions les renfermant. L’invention concerne par ailleurs des méthodes de criblage d’agents thérapeutiques utilisés dans le traitement de pathologies associées avec le gène C12ORF48, comme le cancer (par exemple le cancer du pancréas et le cancer de la prostate) ainsi que des méthodes permettant d’inhiber la croissance cellulaire et de traiter ou d’atténuer un ou plusieurs symptômes de la maladie. L’invention concerne également des produits tels que des molécules bicaténaires, des vecteurs et des compositions les renfermant.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)